Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Shares Outstanding (Weighted Average) (2016 - 2025)

Palisade Bio has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $64.0 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4420.47% to $64.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.0 million through Dec 2025, up 4420.47% year-over-year, with the annual reading at $64.0 million for FY2025, 4420.47% up from the prior year.
  • Shares Outstanding (Weighted Average) was $64.0 million for Q4 2025 at Palisade Bio, up from $5.7 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $64.0 million in Q4 2025 and troughed at $186195.0 in Q4 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $987282.0 (2022), against an average of $5.2 million.
  • Year-over-year, Shares Outstanding (Weighted Average) crashed 93.29% in 2021 and then skyrocketed 4420.47% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $186195.0 in 2021, then surged by 372.79% to $880311.0 in 2022, then plummeted by 48.2% to $456014.0 in 2023, then soared by 210.62% to $1.4 million in 2024, then skyrocketed by 4420.47% to $64.0 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Shares Outstanding (Weighted Average) are $64.0 million (Q4 2025), $5.7 million (Q3 2025), and $4.8 million (Q2 2025).